Skip to main content
. 2021 Feb 1;14(2):113. doi: 10.3390/ph14020113

Figure 2.

Figure 2

Rationalized design of the proposed new pro-apoptotic agents (Series-I-to-III), relying on the pan Bcl-2 inhibitor, obatoclax.